Results: Medical Developments International profit grows 327%

The Medical Developments International (ASX: MVP) share price is up today after reporting profit growth of 327%

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price is on the rise today after the company reported its results for the 2019 financial year (FY19) this morning. MVP shares opened at $4.76, but have since jumped to $4.94 at the time of reporting – a rise of 3.78%.

What were MVP's numbers like?

Here is a summary of the numbers that Medical Development put out his morning:

  • Gross revenue up 19.3% (compared to FY18) to $21.38 million
  • Net revenue up 19.6% to $20.88 million
  • Net profit after tax up 327% to $1.04 million
  • Operating expenses grew 8% due to marketing and insurance costs as well as employee share payments
  • Earnings per share up 293% to 1.61 cents
  • Final dividend of 2 cents per share (fully franked), taking total dividend per share for FY19 to 4 cents
  • Net tangible asset backing per share (as of June 30 2019) at 5.6 cents, up from negative 17.9 cents at the end of FY18.

Medical Developments reported that sales of its flagship Penthrox medicine grew 47% overall, with a 32% rise in Australian sales and a 68% rise in UK sales. Penthrox is yet to be approved by the US Food and Drug Administration (FDA) but hopes to gain approval by the 2023 financial year, pending further trials.

Meanwhile, sales of Respiratory Medical Devices grew 62% in the US market, 111% in the Asian market and 9% in the Australian market, but were down 53% in the UK/EU, leading to an overall decline of 5%. The company hopes to reverse its UK/EU declines during FY20.

Outlook for MVP

MVP reiterated its goal to make Penthrox the "mainstream analgesic of choice around the world". Over the coming year, the company expects to complete the rollout of Penthrox in Europe as well as Asian and Middle Eastern markets, whilst progressing with its pending approvals in the US market as well as the Chinese market.

Advancing work on "producing other analgesic and pharmaceutical products using the intellectual property that is our new manufacturing process" remains part of MVP's long-term plans, as well as consolidating and growing Respiratory Device sales in "the USA, Europe and elsewhere".

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Magnifying glass in front of an open newspaper with paper houses.
Share Market News

How did ASX REITs vs. residential property investment perform in FY25?

We review the share price growth of the largest ASX REITs vs. residential property investment in FY25.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Broker Notes

These ASX 200 shares could rise 55% to 65%

Analysts think these shares are dirt cheap at current levels.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Broker Notes

Why DroneShield, Nickel Industries, and CSL shares could be best buys

Let's see why Bell Potter is so bullish on these shares.

Read more »

A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall
Opinions

2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth

Shaw and Partners portfolio manager James Gerrish says he knows this will be an 'unpopular call'.

Read more »

Animation of a man measuring a percentage sign, symbolising rising interest rates.
Share Market News

Here's what Westpac says the RBA will do with interest rates next week

Are interest rates heading lower again? Let's find out what the banking giant is predicting.

Read more »

A handsome smiling man sits in the front seat of an electric vehicle with his hands on the wheel feeling pleased that the Carsales share price is going up and the company will shortly pay its biggest dividend ever
Share Market News

Are electric vehicle stocks a good investment today?

Did US President Trump just kill the EV industry?

Read more »